The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer

Conclusions: ctDNA shows enormous promise as a sensitive biomarker for monitoring response to many treatment modalities and for targeting therapy. Thus, it is emerging as a new way for guiding treatment decisions—initiating, altering, and ceasing treatments, or prompting investigation into the potential for residual disease. However, many potentially useful ctDNA markers are available and more work is needed to determine which are best suited for specific purposes and for improving specific outcomes.
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research